
Chronic obstructive pulmonary disease (COPD) is a complex inflammatory lung condition causing significant patient burden and healthcare costs. While current treatments like inhalers provide relief, many patients experience symptoms, exacerbations, and declining lung function. Neutrophilic inflammation is common, but 20–40% have type 2 inflammation. Addressing this unmet need requires targeted therapies based on evolving COPD understanding, including epithelial alarmins. This review outlines the treatment landscape, unmet needs, type 2 inflammation, potential biomarkers, and rationale for novel therapies.
Like
Save
Share